Filing Flows

Filing Flows › Maze Therapeutics (MAZE) › Who owns the stock

Who owns Maze Therapeutics (MAZE) stock

155 funds reported Maze Therapeutics (MAZE) shares in their latest 13F filings, worth $1.8B in all. The largest holder is Frazier Life Sciences Management, L.P. ($150M). Last quarter 93 funds added to their stakes and 73 cut them.

Largest holders of MAZE (13F)Largest holders of MAZE (13F)Frazier Life Sciences Management,…$150MTRV GP IV, LLC$134MArch Venture Management, LLC$123MDeep Track Capital, LP$111MBlackRock$105MJupiter Topco LLC$102MJanus Henderson Group$85.3MT. Rowe Price Investment Manageme…$77.7MVanguard Group$70.3MLogos Global Management LP$57.7M

Largest holders (13F)

FundSharesValueChangeQuarter
Frazier Life Sciences Management, L.P.5,032,915$150Mincrease2026-06-30
TRV GP IV, LLC4,473,958$134Munchanged2026-06-30
Arch Venture Management, LLC4,120,053$123Munchanged2026-06-30
Deep Track Capital, LP3,732,569$111Mincrease2026-06-30
BlackRock3,502,841$105Mincrease2026-06-30
Jupiter Topco LLC3,408,045$102Mbase2026-06-30
Janus Henderson Group2,858,876$85.3Mdecrease2026-03-31
T. Rowe Price Investment Management2,603,682$77.7Mnew2026-06-30
Vanguard Group1,697,015$70.3Mincrease2025-12-31
Logos Global Management LP1,935,000$57.7Mincrease2026-06-30
Vanguard Capital Management LLC1,778,222$53.1Mincrease2026-06-30
AH Capital Management, L.L.C.1,702,225$50.8Munchanged2026-06-30
VR Adviser, LLC1,602,034$47.8Munchanged2026-06-30
Alphabet1,388,583$41.4Munchanged2026-06-30
FMR LLC1,056,959$31.5Mincrease2026-06-30

Maze Therapeutics' latest quarter

Maze Therapeutics, Q1 2026: revenue $20.0M, operating margin -132.8%, net loss $24.2M, operating cash flow −$39.1M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most MAZE stock?

By the latest 13F filings: Frazier Life Sciences Management, L.P. ($150M); TRV GP IV, LLC ($134M); Arch Venture Management, LLC ($123M); Deep Track Capital, LP ($111M); BlackRock ($105M).

What is the short interest in MAZE?

7,527,939 shares were sold short at the 2026-10-15 settlement, 14.66% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.